Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Immunodeficiency: early-phase trial registry

4 of 7 indexed Immunodeficiency trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Immunodeficiency: 7 US clinical trials tracked, 4 recruiting.

Immunodeficiency is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition immunodeficiency

OPEN 4 | RECR 57% | LATE 0 | EARLY 4 | RANK #2497 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Immunodeficiency (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Immunodeficiency

Immunodeficiency lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immunodeficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Immunodeficiency is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Immunodeficiency research.

    National Cancer Institute (NCI) accounts for 3 of 7 trials (42.9%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Immunodeficiency enrolment sits around 100 participants.

    Median target enrolment is 100 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.

  4. Immunodeficiency splits between interventional and observational designs.

    4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Top Sponsors

National Cancer Institute (NCI) 3 trials
National Institute of Allergy and Infectious Diseases (NIAID) 2 trials
Ghady Haidar 1 trials
Children's Hospital of Philadelphia 1 trials

Named interventions

Most-linked intervention names on Immunodeficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Allogeneic HSCT Procedure
2 trials
Tacrolimus Drug
2 trials
Evusheld Drug
1 trials
Post-Transplant Cyclophosphamide Drug
1 trials
Hematopoietic Cell Transplant Procedure
1 trials
Phase 2 Established Dose from prior study, NCT03810196 Device
1 trials
Phase 2 Maximum Tolerated Dose determined in Phase 1 Device
1 trials
Phase 1 Dose Level 3 Device
1 trials

US sites by state

Facility locations filed on Immunodeficiency trials. A trial with sites in several states counts in each.

Maryland 5 trials
Pennsylvania 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Immunodeficiency page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immunodeficiency condition card totals 7 registered trials; most-linked intervention Allogeneic HSCT; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.